Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in Interest ReceivablesChange in Net LoansChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Change in Receivables (2016 - 2025)

iBio (IBIO) has disclosed Change in Receivables for 13 consecutive years, with $65000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Receivables changed N/A to $65000.0 in Q3 2025 year-over-year; TTM through Dec 2025 was $65000.0, a 106.71% increase, with the full-year FY2023 number at -$1.0 million, down 212.87% from a year prior.
  • Change in Receivables was $65000.0 for Q3 2025 at iBio, up from -$69000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $893000.0 in Q1 2022 to a low of -$900000.0 in Q1 2023.
  • A 4-year average of $24818.2 and a median of $54000.0 in 2022 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: soared 329.33% in 2022, then plummeted 1625.0% in 2023.
  • iBio's Change in Receivables stood at -$96000.0 in 2021, then grew by 11.46% to -$85000.0 in 2022, then grew by 18.82% to -$69000.0 in 2023, then surged by 194.2% to $65000.0 in 2025.
  • Per Business Quant, the three most recent readings for IBIO's Change in Receivables are $65000.0 (Q3 2025), -$69000.0 (Q2 2023), and -$900000.0 (Q1 2023).